2013 BMT Tandem Meetings: Oral Abstracts - Session A

7

A Phase 1 Trial of the Hematopoietic Growth Factor CDX-301 (rhuFlt3L) in Healthy Volunteers
Niroshana Anandasabapathy, MD, PhD, Rockefeller University; Arlene Hurley, ANP, CCRC, Rockefeller University; Gaelle Breton, PhD, Rockefeller University; Marina Caskey, MD, Rockefeller University; Christine Trumpfheller, PhD, Rockefeller University; Popi Sarma, Rockefeller University; James Pring, Rockefeller University; Maggie Pack, PhD, Rockefeller University; Noreen Buckley, ANP, Rockefeller University; Renee Riggs, Celldex Therapeutics, Inc.; Jennifer Green, Celldex Therapeutics, Inc.; Michael Yellin, MD, Celldex Therapeutics, Inc.; Thomas Davis, MD, Celldex Therapeutics, Inc.; Tibor Keler, PhD, Celldex Therapeutics, Inc.; Sarah Schlesinger, MD, Rockefeller University

8

Similar Survival in Patients with Acute Myeloid Leukemia Relapsing after Matched Related Donor and Umbilical Cord Blood Transplantation
Nelli Bejanyan, MD, University of Minnesota; Betul Oran, MD, MD Anderson Cancer Center; Ryan Shanley, M.S., University of Minnesota; Celalettin Ustun, MD, University of Minnesota; Erica Warlick, MD, University of Minnesota; Michael Richard Verneris, MD, University of Minnesota Medical Center, Fairview; John E. Wagner, MD, University of Minnesota; Daniel J. Weisdorf, MD, University of Minnesota; Claudio G. Brunstein, MD, PhD, University of Minnesota

9

TLI-ATG Conditioning and Allogeneic Transplantation for Patients with MDS and MPN
Jonathan Benjamin, MD, PhD, Stanford University; Saurabh Chhabra, MD, Stanford University; Holbrook Kohrt, MD, Stanford University; Ginna G Laport, MD, Stanford University; Sally Arai, MD, Stanford University; Laura Johnston, MD, Stanford University; David B. Miklos, MD, PhD, Stanford University; Judith A. Shizuru, MD, PhD, Stanford University; Wen-Kai Weng, MD, Stanford University; Robert Negrin, MD, Stanford University; Robert Lowsky, MD, Stanford University

10

Outcomes of Patients Older than Age 70 Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies
Andrew M. Brunner, MD, Massachusetts General Hospital; Yi-Bin Chen, MD, Massachusetts General Hospital; Haesook Kim, PhD, Dana-Farber Cancer Institute; Erin Coughlin, Massachusetts General Hospital; Edwin P. Alyea III, MD, Dana-Farber Cancer Institute; Philippe Armand, MD, PhD, Dana-Farber Cancer Institute; Karen Ballen, MD, Massachusetts General Hospital; Corey Cutler, MD MPH FRCP(C), Dana-Farber Cancer Institute; Bimalangshu R Dey, MD, PhD, Massachusetts General Hospital; Brett Glotzbecker, MD, Beth Israel Deaconess Medical Center; John Koreth, MBBS, DPhil, Dana-Farber Cancer Institute; Steven L. McAfee, MD, Massachusetts General Hospital; Thomas R. Spitzer, MD, Massachusetts General Hospital; Robert J. Soiffer, MD, Dana-Farber Cancer Institute; Joseph H Antin, MD, Dana-Farber Cancer Institute; Vincent T. Ho, MD, Dana-Farber Cancer Institute

11

Busulfan Dose Intensity and Outcomes in Reduced-Intensity Allogeneic Stem Cell Transplantation for MDS/AML
Yi-Bin Chen, MD, Massachusetts General Hospital; Erin Coughlin, Massachusetts General Hospital; Corey Cutler, MD MPH FRCP(C), Dana-Farber Cancer Institute; Kevin Kennedy, MS, Independent Consultant; Edwin P. Alyea III, MD, Dana-Farber Cancer Institute; Philippe Armand, MD, PhD, Dana-Farber Cancer Institute; Eyal C. Attar, MD, Massachusetts General Hospital; Karen Ballen, MD, Massachusetts General Hospital; Bimalangshu R Dey, MD, PhD, Massachusetts General Hospital; John Koreth, MBBS, DPhil, Dana-Farber Cancer Institute; Steven L. McAfee, MD, Massachusetts General Hospital; Thomas R. Spitzer, MD, Massachusetts General Hospital; Joseph H Antin, MD, Dana-Farber Cancer Institute; Robert J. Soiffer, MD, Dana-Farber Cancer Institute; Vincent T. Ho, MD, Dana-Farber Cancer Institute

12

Transplantation Outcomes of 8/8-Matched Unrelated Donors Compared with Matched Siblings and Autologous Transplantation for Acute Myeloid Leukemia with Intermediate Cytogenetics in First Remission
Byung-Sik Cho, Catholic BMT center, Seoul St. Mary's Hospital; Seung-Ah Yahng, Catholic BMT center; Sung-Eun Lee, Catholic BMT center; Ki-Seong Eom, Catholic BMT center; Yoo-Jin Kim, Catholic BMT center; Hee-Je Kim, Catholic Hsct Center, St. Mary's Hospital; Seok Lee, The Catholic University of Korea; Chang-Ki Min, Catholic BMT center; Seok-Goo Cho, Catholic BMT center; Dong-Wook Kim, Catholic BMT center; Jong-Wook Lee, MD. PhD, The Catholic University of Korea; Jae-Ho Yoon, Catholic BMT center; Seung-Hwan Shin, Catholic BMT center; Woo-Sung Min, MD, PhD, St. Mary's Hospital Catholic HSCT Center; Chong Won Park, Catholic BMT center

24

High Engraftment Rates Following Second Allogeneic Transplants for Graft Failure Result in Good Outcomes, On Behalf of the BSBMT
Robert Lown, Anthony Nolan; Paul Veys, Great Ormond Street Hospital for Children; Mary Slatter, Newcastle upon Tyne Hospitals NHS Foundation Trust; Robert Wynn, Royal Manchester Children's Hospital; Adrian Bloor, Christie Hospital; Julia Perry, BSBMT; Rachel Pearce, BSBMT; Keiren Kirkland, BSBMT; Bronwen Shaw, Anthony Nolan

32

Are Outcomes after Myeloablative Conditioning Regimen in Double Cord Blood Transplantation Better than Single UCBT for Adults with Acute Leukemia in Remission?
Annalisa Ruggeri, MD, Eurocord International Registry, Paris, France; Henrique Bittencourt, MD, Hospital de Clinicas; Guillermo Sanz, MD, Hospital Univ. La Fe; Alessandro Rambaldi, USC Hematology and Laboratory of Cell Therapy �G. Lanzani�, Ospedali Riuniti, Bergamo (Italy); Ibrahim Yakoub-Agha, MD, PhD, CHU de Lille; Josep-Maria Ribeira, MD, PhD, IJC-ICO Badalona, Hospital Germans Trias i Pujol, Universitat Aut�noma de Barcelona, Badalona; William Arcese, MD, University; Lionel Mannone, MD, Service d'Hematologie, CHU L'Archet; Jorge Sierra, MD, Hospital de la Santa Creu i Sant Pau; Carlos Solano, MD, Hospital Clinico, Spain; Samir Nabhan, MD, Eurocord International Registry, Paris, France; Luciana Tucunduva, MD, Eurocord International Registry, Paris, France; Fernanda Volt, Eurocord International Registry, Paris, France; Chantal Kenzey, Eurocord International Registry, Paris, France; Eliane Gluckman, MD RFCP, Eurocord; Myriam Labopin, MD, Service d�H�matologie et Th�rapie Cellulaire, AP-HP, UPMC Universit� Paris 6, UMR-S 938, CEREST-TC EBMT, H�pital Saint Antoine; Vanderson Rocha, MD, PhD, Eurocord

S-OA-A Oral Abstracts - Session A - Allogeneic Transplants